Our Blog & Resources

Analytical validation of HRD calculation performed with the OncoDEEP® Kit Comprehensive Genomic Panel

Introduction : HRD validation with OncoDEEP® Kit for ovarian cancer This poster highlights the results of a rigorous study conducted on 76 ovarian carcinoma samples from four Spanish hospitals. The OncoDEEP® kit stands out for...

Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD)

Comprehensive genomic profiling (CGP) and reliable molecular characterization of solid tumors using NGS technology has become a key tool to facilitate biomarker-matched therapy selection. With a broad spectrum of therapies already approved or in clinical...

Enhancing HRD Genomic Scar Result Interpretation: New Insights and Strategies

What is HRD Genomic Scar? The HRD Genomic Scar (GS) is essentially a collection of genetic changes or signatures that indicate a cell’s inability to repair DNA damage effectively using this specific DNA repair pathway....

HRD in Ovarian Cancer Treatment: 60 year-old woman with Metastatic Ovarian Cancer

Detailed case description: HRD’s role in ovarian cancer A 60 year-old woman was diagnosed with high-grade serious ovarian cancer in 2021. She went under surgery followed by platinum-containing adjuvant chemotherapy. After nearly 2 years, she...

White Paper: Homologous Recombination Deficiency (HRD) Assessment for Clinical Management using the OncoDEEP® Kit

The Homologous Recombination Repair (HRR) pathway repairs DNA double-strand breaks (DSB). HRR deficiency leads to the accumulation of genomic aberrations and genomic instability which can promote malignant transformation. This phenotype of loss of the HRR...

The NHS South East Genomic Medicine Service transitions to the OncoDEEP Kit a Solid Tumour Panel that can transform oncology patients’ lives as a result of timely comprehensive genomic testing.

The NHS South East Genomic Medicine Service serves approximately 15.4% of the population of England and seeks to improve patient outcomes through care pathway development enabling timely and equitable access to genomic testing and genomically...

OncoDNA to attend the 36th European Congress of Pathology (ECP) in Florence

OncoDNA is taking part in the 36th European Congress of Pathology (ECP), to be held from 7 to 11 September 2024 in Florence, Italy. This event brings together pathology experts from across Europe to discuss...

Dr. Ofer Elhanani I’m a staff scientist in Dr. Leeat Keren’s lab at the Weizmann Institute of Science in Israel. In our lab, we focus on research questions related to the interactions between tumor cells...

Comprehensive Genomic Profiling of Solid Tumor Patients for Broad Analysis in clinical diagnostics – A Comparative Analysis of OncoDEEP® Kit and Illumina TSO500

Comprehensive Pan-tumor Solution Comprehensive pan-tumor profiling of solid tumor is made possible with OncoDEEP® DNA and RNA Kit solutions. Designed for use with the powerful Next Generation Sequencing (NGS) technology, OncoDEEP® Kits can easily and...

Advancing personalized cancer treatment: Webinar Replay

Webinar replay available now: Unlocking precision medicine through expert NGS panel design Discover the Future of Personalized Cancer Treatment Thank you for your interest in our groundbreaking webinar on the latest advancements in cancer research...

Advancing personalized cancer treatment: explore the synergy of Twist Bioscience and OncoDNA in our webinar

Unlocking precision medicine through expert NGS panel design Tuesday, February 13, 20244:00 PM CEST By Dr. Marcel Trautmann, Koenraad Eycken, Dr. James Flynn Join our webinar to discover revolutionary insights into personalised cancer treatment with...

January: 45-year-old male with an intrahepatic cholangiocarcinoma

We will describe the case of a 45 year old man diagnosed with an intrahepatic cholangiocarcinoma in 2022. He was treated by surgery and had several cycle of chemotherapies. The patient shows signs of resistance...

OncoDEEP Kits enable routine NGS workflow at the Institute of Pathology, Klinikum Region, Hanover, Germany

OncoDNA, a leading genomic and theranostic company specialising in precision medicine for cancer treatment, today has announced the implementation of OncoDEEP® Kit in clinical routine by the Institute of Pathology at the Klinikum Region Hannover...

September: 53 year-old man with Metastatic Colorectal Cancer

Case description: A 53 year-old man was diagnosed with metastatic colorectal cancer. In 2023, the primary sample was tested using our OncoDEEP® Kit. The analysis revealed a FMN1-NTRK3 gene fusion for this patient and a...

July: 53 year-old man with Non-Small Cell Lung Cancer

Case description: A 53 year-old man was diagnosed with a metastatic Non-Small Cell Lung Cancer (mNSCLC) in 2021. This patient was a non-smoker. In 2022, a biopsy from a bone metastasis was tested using our...

Revolutionizing laboratory operations with OncoDEEP® Kit

Biomarker testing is critical to learning more about each patient’s tumor type and can be used to help determine treatment options. Based on the test results, patients may be matched with targeted therapies aimed at...

Comprehensive Ovarian Cancer Treatment and Management

What is Ovarian Cancer? With an estimated 313 959 new cancer cases and 207 252  deaths in women, ovarian cancer is the 7th most commonly diagnosed cancer and the 8th cause of cancer death in...

Comprehensive genomic profiling in oncology: A revolutionary approach by Marcel Trautmann

OncoDNA has received a glowing testimonial from one of the largest German care providers that has selected and incorporated our OncoDEEP Kit in their routine clinical diagnostic oncology screening. We are more than honored to have...

OncoDNA announces the operational launch of its OncoDEEP® Kit for comprehensive genomic profiling of solid tumors

A unique workflow solution integrating a pan-cancer next-generation sequencing (ngs) panel powered by a bioinformatics software suite for customizable biological and clinical interpretation. OncoDNA, a genomic and theranostic company specializing in precision medicine for the...

OncoDNA and Synlab partner to facilitate access to comprehensive biomarker testing for cancer therapy selection in Germany

Synlab laboratories to perform OncoDEEP® biomarker test to help doctors decide on the most effective treatment for their cancer patients. OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer...

OncoDNA launches OncoDEEP® Kit for comprehensive biomarker testing of solid tumors

Unique workflow solution integrating a comprensive pan-cancer NGS panel powered by Twist Bioscience and a bioinformatics software suite. OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic...

OncoDNA and Bergonié Institute to test the clinical utility of blood-and tissue-based biomarker tests in oncology

The Appolo study will assess the impact of biomarker testing on access to precision medicines and on posttreatment surveillance for cancer patients across the sounth of France. OncoDNA, a genomic and theranostic company specializing in...